MAP-kinase interacting kinases (MNKs) are a novel target for the treatment of autism spectrum disorders. We aim to develop a brain-penetrant, small molecule inhibitor that selectively targets MNKs and alleviates the core symptoms of autism.
Funding
Development of brain-penetrant MNK inhibitors
Innosuisse Projekt (GrantsTool), 03.2023-08.2024 (18)
PI : Genç, Özgür,Lill, Markus A.,Scheiffele, Peter.